ria

Ashish Kumar

@stoxbazar.0207
New Delhi
5+ Years of experience
SEBI Registration INH100008939
Ashish Kumar is a highly accomplished professional in the financial services arena and the esteemed Founder of StoxBazar. With a career spanning over a decade, Ashish has gained extensive experience and expertise in various roles such as Engineer, Sr. Equity Analyst, Technical Analyst, and Trainer since 2011. He has ha ... Read more
Trade Ideas
386
Opinions
1k
Followers
71k

Expertise

Quantitative
Growth
Technical
Index Strategies
Swing Trading
Market Commentary
Futures & Options
Technical Analysis
Trade Facts
Total Trades
0
Missed Trades
0
Profit Trades
0
icon0%
Accuracy
Ask me Anything

Got a question? Ask me and I will answer it. Stay curious, stay hungry!

Posts

shared an insight ⚡️ 1 hour ago
MRF shares drop 2% as Q1 profit and margins weaken
MRF
d shares fell about 2% on Tuesday after the tyre major reported a decline in first-quarter profit and operating earnings, even as revenue continued to grow. Consolidated net profit for the June quarter of FY27 slipped 6.52% year-on-year to Rs 479.25 crore, from Rs 512.67 crore a year earlier. Revenue rose 9.64% to Rs 8,415.50 crore, reflecting solid top-line momentum. However, operating performance came under pressure. EBITDA declined 7.46% to Rs 990.63 crore, while the EBITDA margin contracted sharply by 218 basis points to 11.77% from 13.95% in the year-ago period. The margin squeeze was attributed to higher raw-material costs. The stock traded around Rs 1,31,150 in afternoon deals, making it one of the notable losers on the Nifty Midcap 100. The results reverse the stronger margin performance seen in the previous quarter.
17
16
shared an insight ⚡️ 4 hours ago
Gland Pharma Q1 Results Fuel Stock Surge
GLAND
ma reported a robust performance in the April-June quarter, with consolidated net profit rising 47.1% year-on-year to Rs 317 crore from Rs 215 crore. Revenue grew 19.6% to Rs 1,800.2 crore, while EBITDA climbed 33.1% to Rs 489.2 crore. Profit after tax margin expanded by around 330 basis points, reflecting improved operational efficiency. The strong numbers triggered a sharp market reaction. Shares of Gland Pharma jumped nearly 12%, emerging as the top midcap gainer. Brokerage firm Jefferies upgraded the stock to Buy, citing the solid quarter and positive outlook. The results highlight healthy growth in the company’s core injectable and complex generics business, boosting investor confidence amid a challenging pharmaceutical landscape.
68
59
shared an insight ⚡️ 20 hours ago
Paytm shares surge nearly 9% to multi-year high on Bernstein upgrade
Shares of One97 Communications, parent of
PAYTM
tm, jumped nearly 9% on Monday, hitting an intra-day high of Rs 1,565.90 on the NSE. The rally followed Bernstein’s decision to raise its target price to Rs 2,200 from Rs 1,500 while retaining an “outperform” rating. The new target, higher than Paytm’s IPO price of Rs 2,150 for the first time since its 2021 listing, implies over 52% upside from Friday’s close. Bernstein factored in the expected introduction of Merchant Discount Rate (MDR) on select UPI merchant transactions from FY28. Analysts estimate MDR could lift Paytm’s net payments margins by 3-4 basis points and boost FY30 EPS estimates by about 30%. The government has clarified that consumers will not face charges, with MDR applying only to certain merchant transactions above a threshold.
300
55
    Read More Posts →

    FAQ's

    What are the top stock recommendations by Ashish Kumar?

    up
    Ashish Kumar regularly shares stock views and market analysis on StockGro. Some of the stocks they have recently shared views on include MRF, GLAND and PAYTM. Explore Ashish Kumar's complete list of posts and trade views on their StockGro profile.

    How can I follow Ashish Kumar's latest investment insights?

    up
    You can follow Ashish Kumar's latest investment insights, stock recommendations, and market analysis on StockGro App. Additionally, you can check their detailed stock analysis reports in the StockGro blog section.

    What is Ashish Kumar's investment strategy?

    up
    Ashish Kumar follows a data-driven, research-backed investment strategy focused on maximizing returns while managing risk. Their approach includes fundamental and technical analysis, portfolio diversification, and sectoral trends to identify high-potential stocks.

    How long has Ashish Kumar been a SEBI-registered Research Analyst (RA)?

    up
    Ashish Kumar has been a SEBI-registered Research Analyst and have 5+ Years of experience. With extensive experience in stock market analysis and investment research, they have guided investors in making informed and profitable decisions.

    Where can I see Ashish Kumar's past performance and stock picks?

    up
    You can check Ashish Kumar's past stock recommendations, success rate, and investment insights on their StockGro profile. Their historical stock picks reflect a track record of strategic investment decisions based on thorough research.

    How can I contact Ashish Kumar for stock market advice?

    up
    For stock market guidance from Ashish Kumar, you can connect through their StockGro profile. Some RAs may also provide personalized investment consultations based on their availability and SEBI regulations.

    What is Ashish Kumar's track record in predicting market movements?

    up
    Ashish Kumar has a proven track record of accurate market analysis and trend predictions. By analyzing economic indicators, market sentiment, and technical charts, they have consistently helped investors make well-timed investment decisions.

    What is the SEBI Registration number for Ashish Kumar?

    up
    Ashish Kumar is a SEBI-registered Research Analyst with the SEBI Registration INH100008939. This ensures that their investment recommendations comply with SEBI's regulatory framework for investor protection and financial advisory standards.
    Be Financially Free with StockGro